Cardinal Health
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
- Total institutional ownership rose 0.2 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 90.46% +0.22pp
- Institutions
- 1,781 -4
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Jason Hollar | Chief Executive Officer | 0.03% |
| Deborah Weitzman | Chief Executive Officer of Pharmaceutical & Specialty Solutions Segment | 0.03% |
| Ola Snow | Former Chief Human Resources Officer | 0.01% |
| Stephen Mason | Chief Executive Officer of GMPD segment | 0.01% |
| Patricia Hemingway Hall | Independent Chairperson | 0.00% |
| Michelle Greene | Executive VP and Chief Information Officer of Global Technology & Business Services | 0.00% |
| Michelle Brennan | Independent Director | 0.00% |
| Jessica Mayer | Chief Legal & Compliance Officer | 0.00% |
| Anita Zielinski | Senior VP of Finance & Chief Accounting Officer | 0.00% |
| Sheri Edison | Independent Director | 0.00% |
| Valerie Pitteroff | Chief Human Resources Officer | 0.00% |
| Robert Azelby | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Jason Hollar | Chief Executive Officer | Open Market Disposition | -124,529 | $233.22–237.88 |
| 2026-08-18 | Mary Scherer | Senior Vice President | Open Market Disposition | -2,302 | $237.39–237.40 |
| 2026-08-17 | Aaron Alt | Chief Financial Officer | Open Market Disposition | -42,000 | $234.55–237.26 |
| 2026-08-17 | Deborah Weitzman | Chief Executive Officer of Pharmaceutical & Specialty Solutions Segment | Open Market Disposition | -7,354 | $235.30–237.44 |
| 2026-08-17 | Jessica Mayer | Chief Legal & Compliance Officer | Open Market Disposition | -29,436 | $234.64–237.31 |
| 2026-08-17 | Stephen Mason | Chief Executive Officer of GMPD segment | Open Market Disposition | -35,000 | $234.59–237.26 |
| 2026-08-17 | Michelle Greene | Executive VP and Chief Information Officer of Global Technology & Business Services | Open Market Disposition | -11,650 | $234.57–237.25 |
| 2026-08-14 | Jason Hollar | Chief Executive Officer | Sale to Issuer | -103,449 | $235.17 |
| 2026-08-14 | Jason Hollar | Chief Executive Officer | Other Acquisition | +30,616 | -- |
| 2026-08-14 | Aaron Alt | Chief Financial Officer | Sale to Issuer | -30,730 | $235.17 |
| 2026-08-14 | Aaron Alt | Chief Financial Officer | Other Acquisition | +8,079 | -- |
| 2026-08-14 | Deborah Weitzman | Chief Executive Officer of Pharmaceutical & Specialty Solutions Segment | Sale to Issuer | -29,759 | $235.17 |
| 2026-08-14 | Deborah Weitzman | Chief Executive Officer of Pharmaceutical & Specialty Solutions Segment | Other Acquisition | +7,314 | -- |
| 2026-08-14 | Jessica Mayer | Chief Legal & Compliance Officer | Sale to Issuer | -25,285 | $235.17 |
| 2026-08-14 | Jessica Mayer | Chief Legal & Compliance Officer | Other Acquisition | +6,378 | -- |
| 2026-08-14 | Stephen Mason | Chief Executive Officer of GMPD segment | Sale to Issuer | -25,289 | $235.17 |
| 2026-08-14 | Stephen Mason | Chief Executive Officer of GMPD segment | Other Acquisition | +5,868 | -- |
| 2026-08-14 | Michelle Greene | Executive VP and Chief Information Officer of Global Technology & Business Services | Sale to Issuer | -10,031 | $235.17 |
| 2026-08-14 | Michelle Greene | Executive VP and Chief Information Officer of Global Technology & Business Services | Other Acquisition | +2,551 | -- |
| 2026-08-14 | Mary Scherer | Senior Vice President | Sale to Issuer | -1,757 | $235.17 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:34 · For reference only, not investment advice and not tailored to your situation.
Cardinal Health discussion 0 comments